Objective: To compare the adverse effects of adjuvant chemotherapy with ECX and EOX regimen in gastric cancer patients after D2 lymphadenectomy. Methods: prospective longitudinal follow-up study on 85 gastric cancer patients with stage II-III after D2 lymphadenectomy treated ECX regimen (28 patients) and EOX regimen (57 patients) at department of oncology of No.108 Military Central Hospital from 1/2010 to 4/2014. Results: The adverse effects as loss of appetite, fatigue and hands-feet syndrome have seen in 2 groups with similar rate were 100 percent, 78.6 percent in EO group compared to 93 percent, 71,9 percent in the EOX group respectively with p 0.05. The rate of nausea, vomiting and hair loss in ECX group was higher than EOX group 100 percent, 89.3 percent and 100 percent compared to 64.9 percent, 61.4 percent and 81.2 percent respectively with p = 0.001
p = 0.015
p 0.001. The rate of numbness in the extremities was higher in EOX group compared to ECX group is 67.2 percent versus 35.7 percent (p 0.001).